reports
- Carole Braudeau
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
FORTUM FORTUM OYJ
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
MRNA MODERNA INC.
SHA SCHAEFFLER AG
- Farid Bitari
- Nicolas David
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
BIO BB BIOTECH AG
EKI EKINOPS SA
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
ALFEN ALFEN NV
ALCUR ARCURE SA
SHA SCHAEFFLER AG
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
FORTUM FORTUM OYJ
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
MRNA MODERNA INC.
SHA SCHAEFFLER AG
- Carole Braudeau
- Farid Bitari
- Nicolas David
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
BIO BB BIOTECH AG
EKI EKINOPS SA
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
ALFEN ALFEN NV
ALCUR ARCURE SA
SHA SCHAEFFLER AG
- Sinan Doganli
ODDO : German Investment Seminar in NYC – Feedback from first day of m...
We are hosting our 27th German Investment Seminar in New York from 13 to 15 January 2025. In total, 66 companies are participating. Below, we provide some of our initial feedback on the companies, which were present on day one. Among these companies which were presented during the first day, we notably highlight a positive feedback on BASF, Fresenius Medical Care and Merck AG. We also keep our positive ratings on stocks like Commerzbank, Deutsche Telekom and Schaeffler. We maintain our underperf...
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
SHA SCHAEFFLER AG
Charles River Laboratories to Present at J.P. Morgan Healthcare Confer...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation ...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
- Carole Braudeau
- Carole Braudeau
Charles River Introduces Global Biotech Incubator Program
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio,” said Kerstin Dolp...
Charles River Laboratories to Present at Evercore ISI Investor Confere...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...
- Carole Braudeau
Credit Morning 11/20/2024
Grifols: the board considers that Brookfield’s indicative price undervalues the company Teva: S&P upgrades the rating to BB/positive from BB/positiveElior: Results recovered in 2023-24, exceeding expectations. Debt reduction is making headway as planned.Tereos: Sharp decline in EBITDA in Q2 24/25. The financial position is stable thanks to the generation of FCF.>...
- Carole Braudeau
Morning Crédit 20/11/2024
Grifols : le conseil d’administration estime que le prix indicatif proposé par Brookfield sous-évalue la sociétéTeva: S&P upgrades the rating to BB/positive from BB/positiveElior: les résultats se sont redressés 2023/24, dépassant les attentes. Le désendettement progresse comme prévu.Tereos : fort repli de l'EBITDA au T2 24/25. La situation financière est stable grâce à la génération de FCF.>...
Bayer AG: 1 director
A director at Bayer AG bought 11,278 shares at 20.745EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Charles River Laboratories International Inc: 2 directors
A director at Charles River Laboratories International Inc gave away 4,500 shares at 0.000USD and the significance rating of the trade was 13/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
- Christophe-Raphaël Ganet
- Marc Lavaud
- Martin Marandon-Carlhian
- Stephane Houri
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.